Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Donepezil, 5 mg daily Clear all
Completed Phase 4 Interventional Results available

A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment

NCT00934375
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Aricept (donepezil hydrochloride), placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
145 participants
Timeline
2006 – 2007
U.S. locations
49
States / cities
Alabaster, Alabama • Peoria, Arizona • Sun City, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Sep 28, 2026, 6:47 PM EDT
Completed Phase 3 Interventional Results available

Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease

NCT00428389
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rivastigmine 5 cm^2 transdermal patch, Rivastigmine 10 cm^2 transdermal patch
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
23
States / cities
Sun City, Arizona • Costa Mesa, California • Fresno, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2014 · Synced Sep 28, 2026, 6:47 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study

NCT02585934
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
RVT-101, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
61
States / cities
Phoenix, Arizona • Tucson, Arizona • Encino, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 28, 2026, 6:47 PM EDT
Completed Phase 1 Interventional

An Open-Label Trial of Donepezil in Fragile X Syndrome

NCT00220584
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
donepezil
Drug
Lead sponsor
Stanford University
Other
Eligibility
14 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2012 · Synced Sep 28, 2026, 6:47 PM EDT
Completed Phase 2 Interventional Results available

Donepezil HCl & Cognitive Deficits in Autism

NCT00047697
View directory record Official record
Conditions
Autistic Disorder
Interventions
Donepezil HCl, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
8 Years to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 28, 2026, 6:47 PM EDT
Completed Phase 2 Interventional Results available

Effects of Cholinergic Augmentation on Measures of Balance and Gait

NCT02206620
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Donepezil
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
30 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Sep 28, 2026, 6:47 PM EDT
Completed Phase 2 Interventional Results available

Use of Donepezil for Treatment of Cocaine Dependence

NCT00467389
View directory record Official record
Conditions
Cocaine Abuse and Dependence
Interventions
Donepezil, 5 mg daily, Oral Placebo
Drug · Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 28, 2026, 6:47 PM EDT
Terminated Phase 4 Interventional Results available

Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain

NCT01743976
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Sep 28, 2026, 6:47 PM EDT
Completed Phase 3 Interventional

Multicenter Evaluation of Memory Remediation After TBI With Donepezil

NCT02255799
View directory record Official record
Conditions
Traumatic Brain Injury, Memory Deficits
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
4
States / cities
Indianapolis, Indiana • Charlestown, Massachusetts • Elkins Park, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 28, 2026, 6:47 PM EDT
Completed Phase 2 Interventional Results available

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

NCT02580305
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
SUVN-502, Placebo, Donepezil, Memantine
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
71
States / cities
Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 28, 2026, 6:47 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

NCT00754052
View directory record Official record
Conditions
Down Syndrome, Cognitive Dysfunction
Interventions
Aricept (donepezil hydrochloride), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
11 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
San Antonio, Texas • Herndon, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 22, 2018 · Synced Sep 28, 2026, 6:47 PM EDT
Active, not recruiting Early Phase 1 Interventional

Effect of Donepezil on Speech Recognition in Cochlear Implant Users

NCT05438264
View directory record Official record
Conditions
Bilateral Sensorineural Hearing Loss
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 28, 2026, 6:47 PM EDT
Completed Phase 2 Interventional Results available

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (HCl) (Aricept) In Treating Cognitive Dysfunction Exhibited By Children With Down Syndrome

NCT00570128
View directory record Official record
Conditions
Down Syndrome
Interventions
Donepezil HCl, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Sep 28, 2026, 6:47 PM EDT
Completed Phase 2Phase 3 Interventional

The Combination of Donepezil and Cognitive Training for Treating Alcohol Use Disorder

NCT04318639
View directory record Official record
Conditions
Alcohol Use Disorder, Mild Cognitive Impairment
Interventions
Donepazil
Combination Product
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
21 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Sep 28, 2026, 6:47 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults

NCT01345864
View directory record Official record
Conditions
Healthy
Interventions
Scopolamine + Donepezil Placebo + PF-04995274 Placebo, Scopolamine + Donepezil 5 mg + PF-04995274 Placebo, Scopolamine + Donepezil 10mg + PF-04995274 Placebo, Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg, Scopolamine + Donepezil Placebo + PF-04995274 15 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Sep 28, 2026, 6:47 PM EDT
Completed Phase 4 Interventional Results available

Combination Treatment Study for Memory Impairment and Depression

NCT01658228
View directory record Official record
Conditions
Depression, Mild Cognitive Impairment
Interventions
Donepezil, Placebo, Citalopram, Venlafaxine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Sep 28, 2026, 6:47 PM EDT
Completed Phase 2 Interventional Results available

Mayo Acute Stroke Trial for Enhancing Recovery

NCT00805792
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Donepezil
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 28, 2026, 6:47 PM EDT
Terminated Phase 4 Interventional Results available

Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy

NCT00619983
View directory record Official record
Conditions
Diabetic Neuropathic Pain, Chronic Low Back Pain
Interventions
donepezil, duloxetine, donepezil 2.5 mg and duloxetine 30mg, placebo, gabapentin
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Sep 28, 2026, 6:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Treatment of Residual Amblyopia With Donepezil

NCT01584076
View directory record Official record
Conditions
Amblyopia
Interventions
Donepezil, Patching
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts • Waltham, Massachusetts • Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 28, 2026, 6:47 PM EDT
Terminated Phase 3 Interventional Results available

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10

NCT00754013
View directory record Official record
Conditions
Down Syndrome, Cognitive Dysfunction
Interventions
Aricept (Donepezil hydrochloride), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Years to 10 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
San Antonio, Texas • Herndon, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 28, 2026, 6:47 PM EDT
Completed Phase 1 Interventional Results available

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

NCT06285240
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MK-1167, Donepezil, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Hallandale, Florida • Decatur, Georgia • Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 28, 2026, 6:47 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

NCT02769065
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 90 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 28, 2026, 6:47 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

NCT01466088
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil, AZD3480
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Phoenix, Arizona • Brooksville, Florida • Hallandale, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 28, 2026, 6:47 PM EDT
Completed Phase 2 Interventional

An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis

NCT01146509
View directory record Official record
Conditions
Migraine Headache
Interventions
Aricept (donepezil hydrochloride)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
4
States / cities
Chicago, Illinois • Springfield, Missouri • Mount Vernon, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2012 · Synced Sep 28, 2026, 6:47 PM EDT